Trial Profile
A Phase 3b, Multicenter, Open-label, Single-arm, Expanded Access Protocol of Talimogene Laherparepvec for the Treatment of Subjects With Unresected, Stage lllB to IVM1c Melanoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Sep 2018
Price :
$35
*
At a glance
- Drugs Talimogene laherparepvec (Primary)
- Indications Malignant melanoma
- Focus Expanded access; Therapeutic Use
- Sponsors Amgen
- 04 Nov 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 12 Jun 2014 New trial record